Salvatore Catarinicchia

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Castrate Resistant Prostate Cancer (CRPC) is a difficult entity to treat in the spectrum of prostate cancer disease. Recently, Follicle Stimulating Hormone (FSH) has been shown to play an important part in the natural history of prostate cancer disease progression (Crawford et al., 2014). Here, we discuss a now deceased 94 year-old patient who illustrates(More)
  • 1